COMMITTEE on FINANCE

Prescription Drug Pricing Reduction Act of 2019

Government Endorsements:

President Donald Trump

"...working together, the Congress can reduce drug prices substantially from current levels. I have been speaking to Senator Chuck Grassley of Iowa and others in the Congress in order to get something on drug pricing done, and done properly. I am calling for bipartisan legislation that achieves the goal of dramatically lowering prescription drug prices. Get a bill to my desk, and I will sign it into law without delay."

Vice President Mike Pence

"...we've got legislation that's bipartisan legislation. Chuck Grassley, Ron Wyden have worked on in the United States Senate. I've been in meetings in the West Wing where we've talked about this, and the president said pass the bipartisan bill. Put it on my desk. We'll lower prescription drugs for the American people."

The White House

President Donald J. Trump applauds the work of Chairman Grassley and Ranking Member Wyden to lower prescription drug costs and further improve their bipartisan legislation, such as adding a provision to limit monthly out-of-pocket spending for seniors with chronic high costs. ... The White House calls on Congress to act now to give Americans the relief they need by sending bipartisan drug pricing reform to the President's desk this year.

Health and Human Services Secretary Alex Azar

"[Chairman. Grassley] and Sen. Wyden have an incredible, bipartisan package to get drug prices down and lower what seniors pay out of pocket for their drugs. I have worked closely with them. We've gotta get that package to the Senate floor. And we've gotta get that passed out of Congress. It'll bring huge relief for people."

Key Senate Statements

Sen. Susan Collins (R-Maine)

"Nearly a quarter of Maine's population uses the Medicare program and more than 20 percent is covered by Medicaid. The Prescription Drug Pricing Reduction Act would benefit every American, especially seniors and those with disabilities, by expanding access to care and decreasing the outrageous cost of many prescription drugs."



Sen. Steve Daines (R-Mont.)

"America's free market system has nurtured the blockbuster drugs and medical innovations that have cured previously "incurable" diseases and improved the quality of life for seniors managing chronic health conditions. We understand Americans do not want to sacrifice quality and innovation. That's why we are working to make changes that will help improve competition and get more bang for the buck."

Sen. Bill Cassidy (R-La.)

"PDPRA, which passed the Senate Finance Committee in July, begins to restore the balance between incentivizing new drugs and returning true market forces to protect the interests of patients and taxpayers."

Sen. Kevin Cramer (R-N.D.)

"The day-to-day political dramas that shroud "Beltway Insiders" don't represent the wants and needs of most Americans. It's the kitchen table issues, such as the high cost of prescription drugs, that folks in North Dakota, Iowa, and other states want and need solutions for."

Sen. Mike Braun (R-Ind.)

"PDPRA increases transparency and holds drug manufacturers more accountable to federal taxpayers while applying pressure to lower list prices and report more accurate calculations of their rebate obligations. ... Importantly, [PDPRA] saves patients and taxpayers money. A lot of money."

Sen. Lisa Murkowski (R-Alaska)

"This bill puts patient health and pocketbooks first. For the first time ever, it would place a \$3,100 annual cap for out-of-pocket drug costs for seniors and spread out payments for high-cost drug expenses. It lowers the amount that Medicare beneficiaries have to pay for drugs before they hit this out-of-pocket cap."

Sen. Martha McSally (R-Ariz.)

"We are at a point where our seniors are forced to choose between buying groceries and buying a lifesaving prescription. Parents are forced to choose between paying rent and buying insulin for their child. I'm supporting Senator Grassley's bipartisan legislation to hold pharmaceutical companies accountable for their drug costs and ensure that Arizonans are getting the best possible deal for medicine they need."

Sen. Joni Ernst (R-Iowa)

"Iowans from every corner of the state have made it clear that they want to see Congress address the skyrocketing cost of prescription drugs. This issue is a top priority for me and it's why I've been working across the aisle on a number of proposals. ... I applaud my colleague and friend Senator Grassley for his work and steadfast commitment to providing relief to the countless Americans who are struggling to afford their medications."

Organization Endorsements:

AARP

"The time is now for legislation to reduce drug prices. Today's vote [on the Prescription Drug Pricing Reduction Act] is a crucial first step leading up to full Senate action. AARP is deeply committed to winning this fight on behalf of our members and all Americans. We stand with senators who are committed to lowering drug prices and are working to advance this important bill.

AARP represents and advocates on behalf of nearly 38 million older Americans

Alliance for Regenerative Medicine

"ARM applauds the Senate Finance Committee's proposal to encourage the adoption of value-based pricing models for the reimbursement of gene therapies in Medicaid. This bipartisan effort is an important first step..."

ARM is an international organization that advocates on issues relating to regenerative medicine and advanced therapies including gene therapy, cell therapy and tissue engineering.

America's Health Insurance Plans

"We applaud the Committee for coming together in a bipartisan way... Giving Big Pharma meaningful liability and accountability for their high drug prices is essential for keeping premiums low for seniors and reducing costs for taxpayers."

AHIP represents members who provide health care and prescription coverage across the country

Association for Accessible Medicine

"The bipartisan proposal from Senate Finance takes meaningful steps to increase access and reduce the cost of prescription drugs for America's patients."

AAM represents America's manufacturers and distributors of generics and biosimilar drugs.

Better Medicare Alliance

"As a community of 135 ally organizations and more than 400,000 beneficiaries, we are encouraged by the Committee's efforts to bring those protections to individuals with high prescription drug costs."

BMA advocates for Medicare Advantage and quality health care on behalf of seniors.

Blue Cross Blue Shield Association

"The Chairman's Mark contains very important and valuable drug cost protections for seniors and people with disabilities to ensure they have access to the medications they need."

Blue Cross Blue Shield Association is a group of independent organizations providing health coverage across the country.





Campaign for Sustainable Rx Pricing

"We applaud Chairman Grassley and Ranking Member Wyden for their dedication to lowering prescription drug prices for Americans... and look forward to working with committee members to advance measures to hold Big Pharma accountable."

The Campaign for Sustainable Rx Pricing (CSRxP) is a coalition of physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses.

See also: An unprecedented opportunity for Washington to lower drug prices

CATO Institute

"[PDPRA] would not impose price controls on prescription drugs; they would give insurance companies incentives to drive harder bargains with drug manufacturers, to the benefit of taxpayers. They would not increase taxes on anyone; they would reduce wasteful Medicare spending and the burden of government by a projected \$85 billion over 10 years." *CATO is a public policy research organization dedicated to the principles of individual liberty, limited government, free* markets, and peace.

Families USA

"On behalf of the millions of families who are struggling, we urge you to pass this legislation through committee, continue to strengthen it... Never forget you have your constituents' strong support in these efforts."

Families USA, a nonprofit advocacy organization, seeks to advance high-quality, affordable health care for all.

National Organization for Rare Disorders

"On behalf of the 25 to 30 million Americans with one of the over 7,000 known rare diseases, the National Organization for Rare Disorders (NORD) applauds the Committee for its efforts to drive meaningful, bipartisan drug pricing reform."

NORD is a patient advocacy organization dedicated to individuals with rare diseases.

Patients for Affordable Drugs Now

"Americans are demanding action to lower drug prices, and the Senate Finance Committee has taken an important step forward with its proposals today... The package protects innovation and maintains patient access to innovative drugs."

Patients for Affordable Drugs now is run by a blood cancer patients, a breast cancer survivor along with former Democratic and Republican communicators.

Avik Roy

"Senate health care leaders have developed a bipartisan, fiscally responsible way to reduce the cost of the Medicare prescription drug benefit, also known as Medicare Part D." Avik Roy, noted conservative economist, is president of the Foundation for Research on Equal Opportunity

